Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 1, 2010, Pages 1-8

  Li, Ning ^a,b   Gu, Lili ^a   Qu, Linlin ^b   Gong Jianfeng, J ^a,b   Li, Qiurong ^a,b   Zhu, Weiming ^a,b   Li, Jieshou ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Berberine; Caco 2 cell; Pro inflammatory cytokines; Tight junction; Trans epithelial electrical resistance

Indexed keywords

BERBERINE; GAMMA INTERFERON; OCCLUDIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; FLOTILLINS; MEMBRANE PROTEIN; OCLN PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DISRUPTION; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL STRAIN CACO 2; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; INFLAMMATION; INTESTINE EPITHELIUM CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; CACO 2 CELL LINE; CYTOLOGY; DESMOSOME; DRUG EFFECTS; ENDOTHELIUM CELL; IMPEDANCE; INTESTINE MUCOSA; METABOLISM; PERMEABILITY; ULTRASTRUCTURE;

BERBERINE; CACO-2 CELLS; CYTOKINES; DESMOSOMES; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTESTINAL MUCOSA; MEMBRANE PROTEINS; PERMEABILITY; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; OCCLUDIN;

EID: 77951208947     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.02.001     Document Type: Article

References (42)

1. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601-608.
2. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., Geboes K., Rutgeerts P.J. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999, 116:22-28.
3. Balda M.S., Flores-Maldonado C., Cereijido M., Matter K. Multiple domains of occludin are involved in the regulation of paracellular permeability. J. Cell. Biochem. 2000, 78:85-96.
4. Beau I., Cotte-Laffitte J., Amsellem R., Servin A.L. A protein kinase A-dependent mechanism by which rotavirus affects the distribution and mRNA level of the functional tight junction-associated protein, occludin, in human differentiated intestinal Caco-2 cells. J. Virol. 2007, 81:8579-8586.
5. Bruewer M., Luegering A., Kucharzik T., Parkos C.A., Madara J.L., Hopkins A.M., Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 2003, 171:6164-6172.
6. Cereijido M., Contreras R.G., Flores-Benitez D., Flores-Maldonado C., Larre I., Ruiz A., Shoshani L. New diseases derived or associated with the tight junction. Arch. Med. Res. 2007, 38:465-478.
7. Fish S.M., Proujansky R., Reenstra W.W. Synergistic effects of interferon γ and tumour necrosis factor α on T84 cell function. Gut 1999, 45:191-198.
8. Gassler N., Rohr C., Schneider A., Kartenbeck J., Bach A., Obermuller N., Otto H.F., Autschbach F. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281:G216-228.
9. Gu L., Li N., Li Q., Zhang Q., Wang C., Zhu W., Li J. The effect of berberine in vitro on tight junctions in human Caco-2 intestinal epithelial cells. Fitoterapia 2009, 80:241-248.
10. Hollander D. Crohn's disease, TNF-α, and the leaky gut. The chicken or the egg. Am. J. Gastroenterol. 2002, 97:1867-1868.
11. Hsiang C.Y., Wu S.L., Cheng S.E., Ho T.Y. Acetaldehyde-induced interleukin-1β and tumor necrosis factor-α production is inhibited by berberine through nuclear factor-κB signaling pathway in HepG2 cells. J. Biomed. Sci. 2005, 12:791-801.
12. Khin-Maung-U, Myo-Khin, Nyunt-Nyunt-Wai, Aye-Kyaw, Tin-U Clinical trial of berberine in acute watery diarrhoea. Br. Med. J. (Clin. Res. Ed.) 1985, 291:1601-1605.
13. Kong D.X., Li X.J., Tang G.Y., Zhang H.Y. How many traditional Chinese medicine components have been recognized by modern Western medicine? A chemoinformatic analysis and implications for finding multicomponent drugs. ChemMedChem 2008, 3:233-236.
14. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Wang Y., Li Z., Liu J., Jiang J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10:1344-1351.
15. Kuo C.L., Chi C.W., Liu T.Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004, 203:127-137.
16. Li F., Wang H.D., Lu D.X., Wang Y.P., Qi R.B., Fu Y.M., Li C.J. Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice. Acta Pharmacol. Sin. 2006, 27:1199-1205.
17. Li Q., Zhang Q., Wang M., Zhao S., Ma J., Luo N., Li N., Li Y., Xu G., Li J. Interferon-γ and tumor necrosis factor-α disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. Clin. Immunol. 2008, 126:67-80.
18. Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., Said H.M. TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κ B activation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:G367-376.
19. Nones K., Dommels Y.E., Martell S., Butts C., McNabb W.C., Park Z.A., Zhu S., Hedderley D., Barnett M.P., Roy N.C. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br. J. Nutr. 2009, 101:169-181.
20. Nusrat A., Parkos C.A., Verkade P., Foley C.S., Liang T.W., Innis-Whitehouse W., Eastburn K.K., Madara J.L. Tight junctions are membrane microdomains. J. Cell. Sci. 2000, 113(Pt 10):1771-1781.
21. Ozaki H., Ishii K., Horiuchi H., Arai H., Kawamoto T., Okawa K., Iwamatsu A., Kita T. Cutting edge: combined treatment of TNF-α and IFN-γ causes redistribution of junctional adhesion molecule in human endothelial cells. J. Immunol. 1999, 163:553-557.
22. Pan G.Y., Wang G.J., Liu X.D., Fawcett J.P., Xie Y.Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol. Toxicol. 2002, 91:193-197.
23. Pandey M.K., Sung B., Kunnumakkara A.B., Sethi G., Chaturvedi M.M., Aggarwal B.B. Berberine modifies cysteine 179 of IκBα kinase, suppresses nuclear factor-κB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008, 68:5370-5379.
24. Peng W.H., Wu C.R., Chen C.S., Chen C.F., Leu Z.C., Hsieh M.T. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors. Life Sci. 2004, 75:2451-2462.
25. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347:417-429.
26. Prasad S., Mingrino R., Kaukinen K., Hayes K.L., Powell R.M., MacDonald T.T., Collins J.E. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab. Invest. 2005, 85:1139-1162.
27. Rutgeerts P., Vermeire S., Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target. Gut 2007, 56:453-455.
28. Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell. Biol. Toxicol. 2005, 21:1-26.
29. Sanders S.E., Madara J.L., McGuirk D.K., Gelman D.S., Colgan S.P. Assessment of inflammatory events in epithelial permeability: a rapid screening method using fluorescein dextrans. Epithelial Cell Biol. 1995, 4:25-34.
30. Schreiber S., Nikolaus S., Hampe J. Activation of nuclear factor κB inflammatory bowel disease. Gut 1998, 42:477-484.
31. Shamsa F., Ahmadiani A., Khosrokhavar R. Antihistaminic and anticholinergic activity of barberry fruit (Berberis vulgaris) in the guinea-pig ileum. J. Ethnopharmacol. 1999, 64:161-166.
32. Shin D.H., Yu H., Hsu W.H. A paradoxical stimulatory effect of berberine on guinea-pig ileum contractility: possible involvement of acetylcholine release from the postganglionic parasympathetic nerve and cholinesterase inhibition. Life Sci. 1993, 53:1495-1500.
33. Taylor C.T., Baird A.W. Berberine inhibition of electrogenic ion transport in rat colon. Br. J. Pharmacol. 1995, 116:2667-2672.
34. Taylor C.T., Winter D.C., Skelly M.M., O'Donoghue D.P., O'Sullivan G.C., Harvey B.J., Baird A.W. Berberine inhibits ion transport in human colonic epithelia. Eur. J. Pharmacol. 1999, 368:111-118.
35. Turner J.R. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am. J. Pathol. 2006, 169:1901-1909.
36. Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R. Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am. J. Pathol. 2005, 166:409-419.
37. Wang F., Schwarz B.T., Graham W.V., Wang Y., Su L., Clayburgh D.R., Abraham C., Turner J.R. IFN-γ-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 2006, 131:1153-1163.
38. Ye D., Ma I., Ma T.Y. Molecular mechanism of tumor necrosis factor-α modulation of intestinal epithelial tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G496-504.
39. Zhou H., Mineshita S. The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J. Pharmacol. Exp. Ther. 2000, 294:822-829.
40. Zhou L., Wang X., Shao L., Yang Y., Shang W., Yuan G., Jiang B., Li F., Tang J., Jing H., Chen M. Berberine acutely inhibits insulin secretion from β-cells through 3′,5′-cyclic adenosine 5′-monophosphate signaling pathway. Endocrinology 2008, 149:4510-4518.
41. Zhu B., Ahrens F.A. Effect of berberine on intestinal secretion mediated by Escherichia coli heat-stable enterotoxin in jejunum of pigs. Am. J. Vet. Res. 1982, 43:1594-1598.
42. Zolotarevsky Y., Hecht G., Koutsouris A., Gonzalez D.E., Quan C., Tom J., Mrsny R.J., Turner J.R. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002, 123:163-172.